Filing Flows › X4 Pharmaceuticals (XFOR) › Q3 2025
X4 Pharmaceuticals (XFOR) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
X4 Pharmaceuticals (XFOR) reported revenue of $1.6M for the third quarter 2025 (Q3 2025), +180% from a year earlier and -8% from the quarter before.
X4 Pharmaceuticals, Q3 2025: revenue $1.6M (+180% year over year), net loss $29.8M, operating cash flow −$27.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | -8% | +180% |
| Operating profit | −$27.5M | — | — |
| Net earnings | −$29.8M | — | — |
| Operating cash flow | −$27.8M | — | — |
What changed
Revenue was $1.6M in Q3 2025, up 180% year over year and down 8% from the previous quarter.
Operating costs exceeded revenue by $27.5M, an operating margin of -1756.6%. Total costs fell 17% while revenue rose 180%. The quarter ended with a net loss of $29.8M, wider than the previous quarter's $25.7M loss.
Operating cash flow was −$27.8M. Non-cash charges added back $223K of depreciation and amortization and $760K of share-based compensation.
Questions
What was X4 Pharmaceuticals' revenue in the third quarter 2025?
X4 Pharmaceuticals (XFOR) reported revenue of $1.6M for the third quarter 2025 (Q3 2025), +180% from a year earlier and -8% from the quarter before.
Source: X4 Pharmaceuticals 10-Q on SEC EDGAR.